This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sanofi (SNY) Hemophilia A Drug BLA Gets FDA Priority Tag
by Zacks Equity Research
Sanofi's (SNY) BLA filing for efanesoctocog alfa was based on data from the XTEND-1 pivotal phase III study.
Pfizer (PFE) RSV Vaccine Found Effective in Older Adults
by Zacks Equity Research
Based on the positive data from the phase III study on its RSV vaccine candidate, Pfizer plans to file a biologics license application (BLA) to the FDA in fall 2022.
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
by Kinjel Shah
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down
by Zacks Equity Research
Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.
PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation
by Zacks Equity Research
Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).
Pharma Stock Roundup: PFE to Buy GBT, JNJ to Stall Baby Talc Sale Globally From 2023
by Kinjel Shah
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
Denali (DNLI) Q2 Earnings Beat, Pipeline Progress in Focus
by Zacks Equity Research
Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.
BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales
by Zacks Equity Research
Biomarin Pharmaceutical's (BMRN) second-quarter earnings and sales beat estimates. BMRN slightly raises its sales guidance for the year.
Regeneron (REGN) Q2 Earnings & Sales Beat on Eylea, Dupixent
by Zacks Equity Research
Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.
The Zacks Analyst Blog Highlights GSK, Merck, Pfizer, Sanofi and AstraZeneca
by Zacks Equity Research
GSK, Merck, Pfizer, Sanofi and AstraZeneca are part of Zacks top Analyst Blog.
Pharma Stock Roundup: MRK, PFE, SNY Q2 Earnings & Sales Beat, GSK Results Mixed
by Kinjel Shah
GSK plc (GSK), Merck (MRK), Pfizer (PFE), Sanofi (SNY) and AstraZeneca (AZN) announce second-quarter results
What is in Store for Regeneron (REGN) This Earnings Season?
by Zacks Equity Research
Regeneron's (REGN) second-quarter earnings might have gotten a boost from the solid performance of Eylea and Dupixent.
Sanofi (SNY) Q2 Earnings & Sales Beat, Ups 2022 Growth View
by Zacks Equity Research
Sanofi (SNY) beats second-quarter estimates for earnings and sales. Dupixent drives sales growth and a strong recovery in travel vaccines. The company raises its earnings growth guidance for 2022.
Drug, Biotech Stocks' Q2 Earnings on Jul 28: MRK, PFE & More
by Zacks Equity Research
Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Jul 28.
Pharma Stock Roundup: MRK Buys Cancer Drug Rights, SNY Dupixent Kids Study Succeeds
by Kinjel Shah
Merck (MRK) buys co-development rights to prostate cancer candidate. FDA grants full approval to Pfizer's (PFE) COVID-19 vaccine for adolescents.
Sanofi (SNY) Dupixent Esophagitis Kids Study Meets Goal
by Zacks Equity Research
Sanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase III pivotal study in children 1 to 11 years of age.
Sanofi's (SNY) Studies on BTK Inhibitor Put on Hold by FDA
by Zacks Equity Research
Sanofi (SNY) pauses enrollment in late-stage studies evaluating its BTK inhibitor in multiple sclerosis and myasthenia gravis after the FDA places a partial clinical hold on these studies.
The Zacks Analyst Blog Highlights Sanofi, Merck, Novartis, Pfizer and J&J
by Zacks Equity Research
Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.
Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted
by Zacks Equity Research
FDA accepts Regeneron's (REGN) application seeking label expansion for Eylea for an extended period in patients with diabetic retinopathy.
Pharma Stock Roundup: FDA Panel Backs Updated COVID Jabs, EU Nod for SNY, MRK Drugs
by Kinjel Shah
An FDA panel recommends updating COVID-19 booster shots. EU approvals for Sanofi's (SNY) two new drugs and expanded use of Merck's (MRK) Keytruda and Novartis' (NVS) Cosentyx.
Sanofi (SNY) Wins Nod for Nexviadyme & Xenpozyme in Europe
by Zacks Equity Research
Sanofi's (SNY) Nexviadyme is approved for the treatment of both late-onset Pompe disease and infantile-onset Pompe disease. Xenpozyme is approved for non-Central Nervous System (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.
Sanofi (SNY), GSK COVID Booster Jab Effective Against Omicron
by Zacks Equity Research
Data from clinical studies show that Sanofi (SNY) and Glaxo's (GSK) next-generation COVID-19 booster candidate elicits a stronger immune response in adults who received an mRNA vaccine as a primary regimen.
Pharma Stock Roundup: FDA Nod to GSK's MMR Jab & SNY's Dupixent Expanded Use
by Kinjel Shah
European Commission approves Roche's (RHHBY) Tecentriq for a new indication. FDA gives the nod to Glaxo's (GSK) new MMR vaccine and Sanofi (SNY) and Regeneron's (REGN) Dupixent for expanded use.
Sanofi's (SNY) Dupixent Gets FDA Nod for Eczema in Infants
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants with moderate-to-severe atopic dermatitis gets FDA approval.
Lilly (LLY) Eczema Candidate Keeps Skin Clearance for One Year
by Zacks Equity Research
Data from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug maintained improvement in skin clearance and itch relief in 8 of 10 patients for a one-year treatment.